Pasi A. Jänne, MD, PhD

Medical Oncology

Pasi A. Jänne, MD, PhD

View Full Profile

Related Videos

FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD Video

FLAURA2 Lung Cancer Study Presented by Pasi Jänne, MD, PhD

Dana-Farber Cancer Institute's Dr. Pasi Jänne details FLAURA2 which found first-line osimertinib + platinum pemetrexed chemotherapy improved overall survival vs. monotherapy in EGFR mutated non-small cell lung cancer, including poorer prognosis patients.

Pasi Jänne, MD, PhD Discusses Lung Cancer data at AACR24 Video

Pasi Jänne, MD, PhD Discusses Lung Cancer data at AACR24

Dana-Farber's Pasi Jänne, MD, PhD, reports on ctDNA with an EGFR mutation in FLAURA2 trial. The new data shows patients whose blood tested positive before therapy for tumor cell DNA with EGFR mutations stood to gain the most from combination therapy.

Lung Cancer Research at ESMO Video

Lung Cancer Research at ESMO

Dana-Farber's Pasi A. Jänne, MD, PhD, provides insight on DESTINY-Lung01 trial in lung cancer highlighted at ESMO 2021.

ASCO22: Pasi Janne, MD, PhD on lung cancer research Video

ASCO22: Pasi Janne, MD, PhD on lung cancer research

Lung cancer research at #ASCO22. Non-small cell lung cancers with KRAS mutation respond to experimental drug adagrasib which also shows activity in brain metastasis. Dana-Farber's Pasi Janne, MD, PhD, is senior author and explains more.